Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2006-07-14
2010-10-05
Chang, Celia (Department: 1625)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C514S307000, C514S311000, C514S313000, C546S134000, C546S135000, C546S159000, C546S164000, C546S171000
Reexamination Certificate
active
07807694
ABSTRACT:
Compounds which modulate chemokine receptor activities are disclosed. These compounds are preferably tertiary amines comprising tetrahydroquinoline and benzimidazole.
REFERENCES:
patent: 5021409 (1991-06-01), Murrer et al.
patent: 5583131 (1996-12-01), Bridger et al.
patent: 5698546 (1997-12-01), Bridger et al.
patent: 5817807 (1998-10-01), Bridger et al.
patent: 6001826 (1999-12-01), Murrer et al.
patent: 6365583 (2002-04-01), MacFarland et al.
patent: 11-269146 (1999-10-01), None
patent: WO-99/38514 (1999-08-01), None
patent: WO-00/42852 (2000-07-01), None
patent: WO-00/51607 (2000-09-01), None
patent: WO-00/56729 (2000-09-01), None
patent: WO-02/22599 (2002-03-01), None
patent: WO-02/22600 (2002-03-01), None
Este et al. “Activity of idifferent bicyclam . . . ” MOl. Pharm. 55, p. 67-73 (1999).
Abi-Younes et al., Clin. Res. (2000) 86:131-138.
Alkhatib et al., Science (1996) 272:1955-1958.
Arai et al., Eur. J. Haematol. (2000) 64:323-332.
Arenburg et al., J. Leukocyte Biol. (1997) 62:554-562.
Aiuti et al., J. Exp. Med. (1997) 185:111-120.
Baggiolini, Nature (1998) 392:565-568.
Bajetto et al., J. Neurochem. (1999) 73:2348-2357.
Berger et al., Annu. Rev. lmmunol. (1999) 17: 657-700.
Biard-Piechaczyk et al., Virology (2000) 268:329-344.
Blaak et al., Proc. Natl. Acad. Sci. (2000) 97:1269-1274.
Blanco et al., Antimicrobial Agents and Chemother (2000) 44:51-56.
Bleul et al., Nature (1996) 382:829-833.
Bleul et al., J. Exp. Med. (1998) 187:753-762.
Bradstock et al., Leukemia (2000) 14:882-888.
Bridger et al., “Bicyclam Derivatives as HIV Inhibitors” in Advances in Antiviral Drug Design vol. 3, pp. 161-229; Published by JAI press (1999); E. De Clercq (ed.).
Bridger et al., J. Med. Chem. (1999) 42:3971-3981.
Burger et al., Blood (1999) 94:3658-3667.
Buttini et al., Nature Med. (1998) 4:441-446.
Carroll et al., Science (1997) 276:273-276.
Cocchi et al., Science (1995) 270:1811-1815.
Connor and Ho, J. Virol. (1994) 68:4400-4408.
Deng et al., Nature (1996) 381:661-666.
Donzella et al., Nature Medicine (1998) 4:72-77.
Dragic et al., Nature (1996) 381:667-673.
Egberink et al., J. Virol. (1999) 73:6346-6352.
Eitner et al. Transplantation (1998) 66:1551-1557.
Fedyk et al., J. Leukocyte Biol. (1999) 66:667-673.
Feng et al., Science (1996) 272:872-877.
Gonzalo et al., J. Immunol. (2000) 165:499-508.
Gupta et al., J. Biol. Chem. (1998) 7:4282-4287.
Herbein et al., Nature (1998) 395:189-194.
Hesselgesser et al., “Chemokines and Chemokine receptors in the Brain” in Chemokines in Disease, published by Humana Press (1999) Herbert (ed.).
Hesselgesser et al. Curr. Biol. (1997) 7:112-121.
Hesselgesser et al., Curr. Biol. (1998) 8:595-598.
Ishii et al., J. Immunol. (1999) 163:3612-3620.
Lataillade et al., Blood (1999) 95:756-768.
Liu et al., Cell (1996) 86:367-377.
Locati et al., Annu. Rev. Med. (1999) 50:425-40.
Ma et al., Immunity (1999) 10:463-471.
Maekawa et al., Internal Medicine (2000) 39:90-100.
Michael et al., Nature Med. (1997) 3:338-340.
Michael et al., J. Virol. (1998) 72:6040-6047.
Miedema et al., Immune. Rev. (1994) 140:35.
Moore et al., J. Invest. Med. (1998) 46:113-120.
Moore et al., Trends Cardiovasc. Med. (1998) 8:51-58.
Murdoch et al., Blood (2000) 95:3032-3043.
Nagasawa et al., Nature (1996) 382:635-638.
Nagase et al., J. Immunol. (2000) 164:5935-5943.
Nanki et al., J. Immunol. (2000) 164:5010-5014.
Oberlin et al., Nature (1996) 382:833-835.
Obrien et al., Lancet (1997) 349:1219.
Ohagen et al., J. Virol. (1999) 73:897-906.
Peled et al., Science (1999) 283:845-848.
Peled et al., Blood (2000) 95:3289-3296.
Rana et al., J. Virol. (1997) 71:3219-3227.
Rizzuto et al., Science (1998) 280:1949-1953.
Salcedo et al., Am. J. Pathol. (1999) 154:1125-1135.
Samson et al., Nature (1996) 382:722-725.
Sanders et al., J. Neuroscience Res. (2000) 59:671-679.
Schols et al., Antiviral Research (1997) 35:147-156.
Schols et al., J. Exp. Med. (1997) 186:1383-1388.
Schuitemaker et al., J. Virol. (1992) 66:1354-1360.
Sehgal et al., J. Surg. Oncol. (1998) 69:99-104.
Simmons et al., J. Virol. (1998) 72:8453-8457.
Simmons et al., J. Virol. (1996) 70:8355-8360.
Tachibana et al., Nature (1998) 393:591-594.
Tersmette et al., J. Virol. (1998) 62:2026-2032.
Theodorou et al., Lancet (1997) 349:1219-1220.
Viardot et al., Ann. Hematol. (1998) 77:195-197.
Volin et al., Biochem. Biophys Res. Commun. (1998) 242:46-53.
Wyatt et al., Science (1998) 280:1884-1888.
Xia et al., J. Neurovirology (1999) 5:32-41.
Yssel et al., Clinical and Experimental Allergy (1998) 28:104-109.
Zhang et al., AIDS Res. Hum. Retroviruses (1997) 13:1357-1366.
Zhang et al., J. Virol. (1998) 72:9307-9312.
Zhang et al., J. Virol. (1999) 73:3443-3448.
Zheng et al., J. Virol. (1999) 73:8256-8267.
Zou et al., Nature, (1998) 393:591-594.
U.S. Appl. No. 60/172,153, filed Dec. 17, 1999.
U.S. Appl. No. 09/111,895, filed Jul. 8, 1998.
U.S. Appl. No. 09/535,314, filed Mar. 24, 2000.
Atsma Bem
Bogucki David
Bridger Gary
Crawford Jason
Di Fluri Maria Rosaria
Chang Celia
Genzyme Corporation
Morrison & Foerster / LLP
LandOfFree
Chemokine receptor binding heterocyclic compounds does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Chemokine receptor binding heterocyclic compounds, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Chemokine receptor binding heterocyclic compounds will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4202217